Publications
View AllPembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant res...
Affiliated Researchers
Institution Info
- Type
- healthcare
- Country
- JP
- Publications
- 3
- Citations
- 4,937
External Links
Identifiers
- ROR
- https://ror.org/00b6s9f18